Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T

Inclusion criteria

• Cancer of prostate
• Evidence of metastasis
• Failed available therapies
• Resolution of any toxic effects of previous therapies
• Performance status (ECOG PS) 0-2
• Adequate hematologic, coagulation (INR 2-3max), hepatic and renal function
• Life expectancy of 12 months
• Agrees to contraceptive use while on study if sexually active
• Sign informed consent document

Exclusion criteria

• Any condition presenting an unacceptably high anesthetic or surgical risk
• HIV positive
• Cognitive impairment such as to preclude informed consent
• Other surgical treatment, chemotherapy and radiation within four weeks of baseline
• Inadequate hematologic, coagulation (INR >3), hepatic, renal function
• Hepatic blood flow abnormalities and/or large-volume ascites
• Concurrent cancer of any other type except skin cancer (excluding melanoma)
• History of allergic reactions to mouse antigens
• Active infection, congestive heart failure, unstable angina, serious cardiac arrhythmias, psychiatric illness, difficult social situations not permitting reliable participation, active bleeding